Gin Hwa Biotech Inc

Gin Hwa Biotech Inc maintains a debt-to-equity ratio of 0.44, indicating a relatively conservative capital structure. The company's liquidity position is characterized by a current ratio of 2.77, supported by cash and equivalents of TWD 116.5 million. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 14.14% and a return on assets (ROA) of 8.78%, both exceeding the industry median for Food Processing. The company's gross margin of 31.76% (TWD 138.2 million gross profit on TWD 435.1 million revenue) is in line with industry norms, but its operating margin of 19.33% (TWD 84.1 million operating income) suggests strong cost control. The company's revenue is concentrated in the Taiwan market, with no disclosed international revenue segments. Its business model is heavily reliant on contract manufacturing for health food products, including liquid, frozen, powder, and capsule forms. The company's exposure to a single geographic market increases its vulnerability to local economic and regulatory shifts. Looking ahead, the company's revenue is projected to grow by 4.5% in the current fiscal year and 3.2% in the next fiscal year, based on historical revenue trends and industry demand for health and supplement products. The company's free cash flow has turned negative in recent periods, with a TWD -26.3 million outflow, primarily due to capital expenditures of TWD -120.7 million. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The negative net cash position after debt is a key flag, and the company's free cash flow has turned negative, which could necessitate external financing. No dilutive events have been disclosed in recent filings, and the company's shares outstanding have remained unchanged. Recent events include the company's 2023 annual report, which outlines its strategic focus on expanding its contract manufacturing capabilities and enhancing product development for health food brands. The company has not disclosed any material regulatory or legal proceedings in its recent filings.